Please assess the completion status of the following clinical trial:

Trial Title: Latiglutenase as a Treatment for Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy confirmed CD diagnosis~* Self-reported adherence to a gluten-free diet for ≥ 12 months~* Agree to maintain dosing of approved prescribed and OTC medications~* Willing to take study treatment with evening meal during any single day~* Willing to take gluten foodstuff with evening meal during any single day~* Willing to maintain GFD for entire study duration~* Willing to agree to minimal ingestion outside of three main daily meals~* Willing and able to comply with all study procedures~* Access to the internet via smartphone, tablet, computer or equivalent to facilitate daily symptom reporting~* Must sign informed consent~Exclusion Criteria:~* Active dermatitis herpetiformis at the time of screening~* IBS (Irritable Bowel Syndrome)~* History of any form of colitis~* Received any systemic biologics (such as monoclonal antibodies or other protein therapeutics where the half-life overlaps with the study start) within 6 months prior to study start~* Taking any oral probiotic supplements (not including probiotics contained in commercially available food preparations) 6 months prior to entry~* Use of any immunosuppressive medications (i.e., for chronic treatment of autoimmune disease or transplant-rejection prophylaxis) 6 months prior to entry~* History of alcohol abuse, illegal drug use~* Unwilling to practice highly effective birth control (unless surgically sterilized or post-menopausal)~* Received any experimental drug within 30 days of randomization, in the case of experimental biologics at least 6 months prior to randomization~* Uncontrolled complications of celiac disease, which, in the opinion of the investigator, could affect immune response or pose an increased risk to the patient~* Inability to give informed consent~* Any medical condition, other than celiac disease, which, in the opinion of the investigator, could adversely affect the patient's participation in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Latiglutenase (Type: ACTIVE_COMPARATOR): IMGX003
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).